Clinical trials: Metastatic Renal Cancer
Kidney Cancer
Biological Therapy Plus Chemotherapy in Treating Patients With Metastatic or Recurrent Kidney Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00003585
- Testing
- aldesleukin, recombinant interferon alfa, fluorouracil
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of New Mexico
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standard therapy available or are…
- Conditions
- Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Pancreas Adenocarcinoma, Biliary Tract Cancer
- Trial name
- NCT06451497
- Testing
- ZM008
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Zumutor Biologics Inc.
Prostate Cancer, Bladder Cancer
Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers
Background: People with prostate, bladder, or kidney cancer often have their cancer spread (metastasize) to lymph nodes. It is important for your doctor to know if this has occurred but currently it can be hard to determine if…
- Conditions
- Prostate Cancer, Bladder Cancer, Kidney Cancer
- Trial name
- NCT02141490
- Testing
- Ferumoxytol, Magnetic Resonance Imaging (MRI)
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors
A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors
The proposed clinical trial is a phase I, open-label, multi-center, dose-escalation study of ALT-803 in patients with surgically incurable advanced solid tumors: melanoma, renal cell, non-small cell lung and squamous cell head…
- Trial name
- NCT01946789
- Testing
- ALT-803
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Altor BioScience
Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Occupational Therapy Fatigue Management-Based Intervention for Metastatic Renal Cell Carcinoma
This clinical trial studies the effects of occupational therapy fatigue management in patients with renal cell cancer that has spread to other places in the body (metastatic).
- Trial name
- NCT04961320
- Testing
- Occupational Therapy, Questionnaire Administration
- Sponsor
- City of Hope Medical Center
Renal Cell Carcinoma
Stereotactic Body Radiotherapy (SBRT) and Sorafenib in Patients With Metastatic, Recurrent, or Unresectable Renal Cell Cancer (RCC)
The purpose of this study is to determine the safety and efficacy of combined stereotactic body radiotherapy (SBRT) + sorafenib in the treatment of patients with Stage IV renal cell carcinoma (RCC) who have recurred locally…
- Trial name
- NCT00672178
- Testing
- Stereotactic body radiation
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Duke University
Colorectal Cancer Metastatic, Triple Negative Breast Cancer
A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors
This study is being conducted to assess the safety, tolerability, and efficacy of EDP1503 alone and in combination with pembrolizumab in patients with advanced metastatic colorectal carcinoma, triple-negative breast cancer, and…
- Conditions
- Colorectal Cancer Metastatic, Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Bladder Cancer
- Trial name
- NCT03775850
- Testing
- EDP1503, Pembrolizumab
- Where
- 8 sites in United States, Canada
- Volunteers
- 69 people
- Sponsor
- Evelo Biosciences, Inc.
Patients With Locally Advanced or Metastatic But Resectable Clear Cell Renal Cell Carcinoma
A Phase 2 Multicenter Single-Arm Clinical Trial of Zanzalintinib and Pembrolizumab in Subjects With Resectable Clear Cell Renal Cell Carcinoma
This is a multicenter, single-arm, phase 2 clinical trial designed to evaluate the clinical efficacy of combination therapy with zanzalintinib and pembrolizumab in patients with locally advanced intermediate- to high-risk…
- Trial name
- NCT07691476
- Testing
- Zanzalintinib and Pembrolizumab
- Volunteers
- 48 people
- Sponsor
- Yonsei University
Renal Cell Carcinoma
Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma
The purpose of this study was to determine the maximum tolerated dose, safety, and effectiveness of lenalidomide (CC-5013) administered in combination with sunitinib as treatment for patients with renal cell carcinoma.
- Trial name
- NCT00975806
- Testing
- Lenalidomide, Sunitinib
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Celgene
Renal Cell Carcinoma, Metastases
A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma
The primary purpose of the study is to assess the potential benefit of combining two targeted therapies (an anti-EGF inhibitor along with an anti-VEGF inhibitor).
- Trial name
- NCT00081614
- Testing
- Avastin (bevacizumab), Tarceva (erlotinib HCl)
- Where
- 20 sites in United States
- Volunteers
- 100 people
- Sponsor
- Genentech, Inc.
Metastatic Clear Cell Renal Cell Carcinoma
68Ga-NY104 PET/CT in Patients With Metastatic Clear Cell Renal Cell Carcinoma
This is a prospective, single-center, single-arm, comparative phase 2 study in patients with metastatic clear cell renal cell carcinoma.
- Trial name
- NCT05879471
- Testing
- 68Ga-NY104 PET/CT
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Peking Union Medical College Hospital
Advanced Renal Cell Carcinoma
IVAC-RCC-001: A Personalized Neoantigen Vaccine as Add-on to Standard of Care Checkpoint Inhibitor in Advanced/Metastatic RCC Patients
This is a monocenter, single-arm, prospective phase Ib trial, designed to evaluate the safety, clinical toxicity and in vivo immunological effects of a patient-individualized peptide vaccination added to standard of care…
- Trial name
- NCT05641545
- Testing
- IVAC
- Where
- Germany
- Volunteers
- 1 people
- Sponsor
- SLK Kliniken Heilbronn GmbH
Metastatic Kidney Cancers
ELR+CXCL Cytokines in Metastatic Kidney Cancers: Predictive Markers of Resistance to Sunitinib
Metastatic renal cell carcinomas (mRCC) are highly angiogenic tumors because of mutation of the pVHL gene leading to over-expression of VEGF.
- Trial name
- SUNITRES (NCT03097601)
- Testing
- ELR+CXCL cytokines levels are of sunitinib response
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Centre Antoine Lacassagne
Renal Cell Carcinoma
89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
This is an exploratory clinical trial to assess the potential of 89Zr-DFO-Atezolizumab Positron Emission Tomography/Computed Tomography (PET/CT) scans in patients with locally advanced or metastatic renal cell carcinoma (RCC).
- Trial name
- NCT04006522
- Testing
- 89Zr-DFO-Atezolizumab, Positron Emission Tomography/Computed Tomography
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- James Brugarolas
Cancer of Kidney
Cabo-POLARIS : A Trial to Evaluate Cabozantinib Among Haemodialysied Patients
Among patients with renal cell carcinoma (RCC), 2.7 to 4.7 % of patients are at risk of progressing to dialysis or transplantation after partial and radical nephrectomy respectively.
- Trial name
- Cabo-POLARIS (NCT05241561)
- Testing
- Cabozantinib, Blood sample, Questionnaires of quality of life
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Metastatic Renal Cell Carcinoma
Functional Imaging in the Assessment of mRCC Response to Sunitinib
The aim of this study is to assess whether functional magnetic resonance imaging (MRI) techniques are able to detect which patients with metastatic renal cell carcinoma will derive benefit from treatment with anti-angiogenic…
- Trial name
- NCT01977586
- Testing
- Magnetic Resonance Imaging (MRI)
- Where
- United Kingdom
- Sponsor
- Imperial College Healthcare NHS Trust
Carcinoma, Renal Cell
Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC
The purpose of this study is to evaluate the combination of Pegylated Alfa Interferon (PEG-Intron), Sunitinib and Tarceva to see if this drug combination delays the disease progression of patients with metastatic Renal Cell…
- Trial name
- NCT00522249
- Testing
- Pegylated Alfa Interferon, sunitinib, erlotinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- The Methodist Hospital Research Institute
Kidney Cancer, Melanoma (Skin)
Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer
RATIONALE: Interleukin-7 may stimulate the white blood cells to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of interleukin-7 in treating patients with metastatic melanoma or locally…
- Trial name
- NCT00492440
- Testing
- recombinant interleukin-7, gene expression analysis, polymerase chain reaction
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Cytheris SA
Neoplasms
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
The primary objective of this trial is to evaluate the efficacy and safety of BI 6727 in patients with locally advanced, metastatic or recurrent urothelial cancer after failure of first line or adjuvant/neoadjuvant chemotherapy.
- Trial name
- NCT01023958
- Testing
- BI 6727, IV infusion
- Where
- 21 sites in United States, Taiwan
- Volunteers
- 50 people
- Sponsor
- Boehringer Ingelheim
Clear Cell Metastatic Renal Cell Carcinoma
Stereotactic Radiotherapy for Metastatic Kidney Cancer Being Treated With Sunitinib
Stereotactic radiotherapy (SRT) is a newer type of focused radiation therapy that precisely and accurately delivers high dose radiation to a tumour, while sparing much of the nearby normal organs.
- Trial name
- NCT02019576
- Testing
- Stereotactic radiotherapy
- Where
- 12 sites in Canada
- Volunteers
- 38 people
- Sponsor
- Sunnybrook Health Sciences Centre
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.